NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

$200,000 plus for a treatment that only shows an alleged 5 year survival advantage beyond SOC in about 5% of patients, and you don't think NICE will have a problem with it?  Unless they can narrow it down to a higher response rate subgroup that means that about 87% won't respond more than a few months.